Vertex Pharamceuticals (VRTX) +54% premarket after positive results in Phase II trials in which its Kalydeco cystic fibrosis drug was used in combination with a second therapy called VX-809. However, the sample was just 48 patients and the big test will come in Phase III
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/